Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to $13.0 million.

  • Heron Therapeutics' Share-based Compensation rose 4.78% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year decrease of 30.26%. This contributed to the annual value of $13.0 million for FY2024, which is 60.55% down from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Share-based Compensation is $13.0 million, which was down 60.55% from $32.9 million recorded in FY2023.
  • Heron Therapeutics' 5-year Share-based Compensation high stood at $50.2 million for FY2020, and its period low was $13.0 million during FY2024.
  • Moreover, its 3-year median value for Share-based Compensation was $32.9 million (2023), whereas its average is $29.6 million.
  • Data for Heron Therapeutics' Share-based Compensation shows a maximum YoY plummeted of 60.55% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Heron Therapeutics' Share-based Compensation stood at $50.2 million in 2020, then decreased by 6.70% to $46.9 million in 2021, then decreased by 8.26% to $43.0 million in 2022, then dropped by 23.56% to $32.9 million in 2023, then tumbled by 60.55% to $13.0 million in 2024.